CXCR2 and acute myeloid leukemia: Blocking CXCR2 activity using an inhibitor increases the susceptibility of AML cells to FLT3 tyrosine kinase inhibitors, potentially offering a promising therapeutic approach in treating AML with FLT3 gene mutations.